Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

VIEW is a prestigious journal published by WILEY that focuses on the rapidly evolving fields of Biomaterials and Biomedical Engineering. Since its inception in 2020, VIEW has established itself as an open-access platform dedicated to disseminating high-quality research and innovation within these disciplines. With an impressive impact factor that places it in the Q1 category of both Biomaterials and Biomedical Engineering, VIEW ranks among the top journals in its field, boasting a 91st percentile ranking in Biomedical Engineering and an 85th percentile ranking in Materials Science. Researchers, professionals, and students are encouraged to utilize this invaluable resource, as it provides a comprehensive view of current advancements and future trends in biomaterial science and engineering. Positioned in the United Kingdom, VIEW operates as a vital scholarly communication link, fostering collaboration and knowledge sharing within an ever-growing global community.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Medicine Nucleaire-Imagerie Fonctionnelle et Metabolique is a prominent journal published by Elsevier France-Editions Scientifiques Medicales Elsevier, dedicated to the specialized fields of nuclear medicine and functional imaging. With an ISSN of 0928-1258 and an E-ISSN of 1878-6820, this esteemed publication has been a crucial platform for the dissemination of research and developments in the discipline since its inception in 1993. Covering a wide array of topics within biophysics, radiological and ultrasound technology, and radiology, the journal currently holds a Q4 category ranking in these fields, reflecting its significance within the academic community. Although there are currently no open access options available for readers, the journal caters to a niche audience of researchers, professionals, and students who seek to enhance their understanding of metabolic imaging and its applications. The 2023 Scopus ranks indicate its position as an emerging source of knowledge in a competitive landscape, making it an important resource for the latest studies and innovations in nuclear medicine.

Advanced Therapeutics, published by WILEY in the United Kingdom, stands at the forefront of medical and pharmaceutical research, offering invaluable insights from 2018 to 2024. This distinguished journal, with an E-ISSN of 2366-3987, is recognized for its exceptional academic rigor, boasting an impressive array of Q1 categorizations in essential fields such as Biochemistry (medical), Pharmaceutical Science, and Pharmacology. With its strategic focus on interdisciplinary studies and cutting-edge therapeutic developments, Advanced Therapeutics serves as a vital resource for researchers, professionals, and students keen on advancing their knowledge and contributing to the evolving landscape of medicine and genetics. The journal's high Scopus rankings further affirm its impact, with significant placements in multiple categories underscoring the quality of published research. Although the journal operates under a subscription model, its accessibility to high-impact findings ensures that it remains a pivotal platform for innovative discourse in therapeutics.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

IMMUNOLOGICAL INVESTIGATIONS, published by Taylor & Francis Inc, is a leading journal in the field of immunology and related medical sciences, with an established presence since 1972. With a focus on cutting-edge research and critical insights in immunological methods and theories, this journal serves as a pivotal platform for researchers, professionals, and students alike. Though it currently holds a Q3 ranking in Immunology and a Q2 ranking in miscellaneous medicine as of 2023, its Scopus rank of #129 out of 236 reflects its dedication to advancing the understanding of immune responses and therapies. The journal's commitment to rigorous peer review and high-quality publications enables it to remain relevant and influential in the ever-evolving landscape of immunological research. Subscription is required to access its extensive archive, which spans critical developments in the field of immunology from 1972 to 2024.

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

BioImpacts, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, is a prominent platform dedicated to advancing the fields of Biochemistry, Genetics, Molecular Biology, Medicine, and Pharmaceutical Science. Established in 2011, this Open Access journal ensures that vital research findings are freely accessible to the global academic community. With an impressive presence in the Scopus database, BioImpacts currently holds a Q2 quartile ranking in its respective categories, reflecting its contribution to scientific discourse and its importance as a critical resource for researchers and practitioners alike. The journal's dynamic scope encompasses a wide range of topics, highlighting innovative research that addresses contemporary challenges in health and disease. Operating out of Tabriz, Iran, BioImpacts is committed to fostering interdisciplinary collaboration and knowledge dissemination through their dedicated publication efforts, which span from 2011 to 2024. Researchers, professionals, and students are encouraged to explore the rich content and cutting-edge studies presented in this journal, making it an indispensable resource in the scientific community.